FDA Clear On Supplement Ingredient Petitions, But Still Fuzzy On Sec. 912
This article was originally published in The Tan Sheet
FDA says current dietary supplement regulations make clear that citizen petitions can be filed to request approval of ingredients that were studied in clinical trials and were part of unsuccessful investigational new drug applications
You may also be interested in...
FDA rejects Ovos Natural Health's citizen petition to classify homotaurine as a dietary ingredient, but leaves the door open for future attempts on the pathway Ovos tried to navigate – moving a substance from failed investigational new drug to dietary supplement.
An FDA draft guidance that seeks to clarify when an investigational new drug application should be filed may add logistical knots to the process of studying foods and dietary ingredients, stakeholders say.
FDA significantly overhauls a health claim linking phytosterols to a reduced risk of coronary heart disease, expanding the type of enriched conventional foods and forms of dietary supplements that can make the claim.